Sjögrenʼs Disease Associated with Severe Retinal Vasculitis and/or Necrotizing Scleritis: Two Cases

Introduction

Sjögrenʼs syndrome is a systemic autoimmune disease with numerous manifestations as it can affect the entire body, which, in turn, makes a diagnosis difficult. It is characterized by lymphocytic infiltration of the salivary and lacrimal glands, which results in sicca syndrome. Depending on the severity of the damaged gland, symptoms such as xerophtalmia, xerostomia, or dry skin can be more or less important. The diagnosis is based on the AECG (American-European Consensus Group) consensus criteria with the presence of a nodular salivary gland infiltration of grade III or the presence of anti-SS-A (Ro) (Anti-Sjögrenʼs-syndrome-related antigen A) or anti-SS-B (La) (Anti-Sjögrenʼs-syndrome-related antigen B) antibodies [1].

• References

• 1 Vitali C, Bombardieri S, Jonsson R. et al. Classification criteria for Sjögrenʼs syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002; 61: 554-558
• 2 Both T, Dalm VA, van Hagen PM. et al. Reviewing primary Sjögrenʼs syndrome: beyond the dryness – From pathophysiology to diagnosis and treatment. Int J Med Sci 2017; 14: 191-200
• 3 Boke W, Thiel HJ, Winter R. [Corneal pathology in rheumatoid arthritis and Sjögren-syndrome with special reference to “rheumatoid keratomalacia”]. Klin Monatsbl Augenheilkd 1976; 168: 483-492
• 4 Cohen KL. Sterile corneal perforation after cataract surgery in Sjögrenʼs syndrome. Br J Ophthalmol 1982; 66: 179-182
• 5 Vivino FB, Minerva P, Huang CH. et al. Corneal melt as the initial presentation of primary Sjögrenʼs syndrome. J Rheumatol 2001; 28: 379-382
• 6 Choi W, Lee SS, Park YG. et al. A case of necrotizing keratoscleritis in primary Sjogrenʼs syndrome. Korean J Ophthalmol 2011; 25: 275-277
• 7 Scofield RH. Vasculitis in Sjögrenʼs syndrome. Curr Rheumatol Rep 2011; 13: 482-488
• 8 Carsons SE, Vivino FB, Parke A. et al. Treatment guidelines for rheumatologic manifestations of Sjögrenʼs syndrome: use of biologic agents, management of fatigue, and inflammatory musculoskeletal pain. Arthritis Care Res (Hoboken) 2017; 69: 517-527
• 9 Marino A, Narula S, Lerman MA. First pediatric patient with neuromyelitis optica and Sjögren syndrome successfully treated with tocilizumab. Pediatr Neurol 2017; 73: e5-e6
• 10 Komai T, Shoda H, Yamaguchi K. et al. Neuromyelitis optica spectrum disorder complicated with Sjogren syndrome successfully treated with tocilizumab: A case report. Mod Rheumatol 2016; 26: 294-296